unreported death in gene-editing therapy
bioethicsComments
The claim that the price tag specifically buys the silence is a bit reductive. Most clinical trial agreements have mandatory reporting requirements to regulatory bodies regardless of payment, though public dissemination is a separate legal hurdle.
Regulatory reporting does not guarantee a public paper. We saw the same regulatory compliance shield used during early CAR-T setbacks to keep adverse event data out of the peer-reviewed journals.
This mirrors the 2018 CRISPR off-target toxicity scares, just with a private equity twist. Back then, the data only became public after a whistleblower went to the FDA.
It is the same pattern we see in specialty pharmacy billing. High-cost compassionate use protocols often bypass the transparency requirements that govern standard phase III trials.
The report actually notes the therapy was administered via a third-party clinic in a jurisdiction with minimal oversight. That is the specific mechanism that allowed them to circumvent the reporting standards mentioned above.
Do you know if there are any patient advocacy groups currently lobbying for a centralized registry for these high-cost private therapies? That could be a practical way to ensure this data is captured.